SCHEDULE 13G 0001633313 XXXXXXXX LIVE Ordinary Shares, par value $0.0001 per share 09/30/2025 0001888886 Structure Therapeutics Inc. 86366E106 601 GATEWAY BLVD SUITE 900 South San Francisco CA 94080 Rule 13d-1(b) Avoro Capital Advisors LLC b DE 16216665.00 0.00 16216665.00 0.00 16216665.00 N 9.38 IA OO Represented by 5,405,555 ADSs (including 750,000 Ordinary Shares (represented by 250,000 ADSs) issuable upon exercise of options). Aghazadeh Behzad b X1 16216665.00 0.00 16216665.00 0.00 16216665.00 N 9.38 HC IN Represented by 5,405,555 ADSs (including 750,000 Ordinary Shares (represented by 250,000 ADSs) issuable upon exercise of options). Structure Therapeutics Inc. 601 Gateway Blvd., Suite 900, South San Francisco, California 94080 This statement is filed by: (i) Avoro Capital Advisors LLC, a Delaware limited liability company ("Avoro"), which provides investment advisory and management services and has acquired American Depositary Shares, each representing three ordinary shares, par value $0.0001 per share ("Ordinary Shares") of Structure Therapeutics, Inc., a Cayman Islands exempted company (the "Company") and call options to purchase ADSs, solely for investment purposes on behalf of Avoro Life Sciences Fund LLC, a Delaware limited liability company, and (ii) Behzad Aghazadeh ("Dr. Aghazadeh," and together with Avoro, the "Reporting Persons"), who serves as the portfolio manager and controlling person of Avoro. The filing of this statement should not be construed as an admission that any Reporting Person is, for purposes of Section 13 of the Act, the beneficial owner of the securities reported herein. There is no CUSIP number assigned to the Ordinary Shares. CUSIP number 86366E106 has been assigned to the American Depositary Shares ("ADSs") of the Issuer, which are quoted on the Nasdaq Global Market under the trading symbol "GPCR." Each ADS represents three (3) Ordinary Shares. The address of the business office of each of the Reporting Persons is 110 Greene Street, Suite 800, New York, NY 10012. Avoro is a Delaware limited liability company. Dr. Aghazadeh is a United States citizen. N IA HC The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 172,793,818 Ordinary Shares outstanding as of July 31, 2025, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2025, filed with the Securities and Exchange Commission on August 6, 2025. 9.38% The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Y N See Item 2(a). Avoro Life Sciences Fund LLC has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5% of the Ordinary Shares. Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Exhibit 99.1: Joint Filing Agreement Avoro Capital Advisors LLC /s/ Scott Epstein 11/14/2025 Aghazadeh Behzad /s/ Behzad Aghazadeh 11/14/2025